The government has confirmed a comprehensive review of its £330 million NHS contract with US data analytics firm Palantir, with a decision due before a break clause falls in early 2027.

NHS Federated Data Platform Under Scrutiny as Ministers Weigh Palantir Exit Ahead of Contract Decision

The decision point that many in NHS digital circles have been quietly tracking for months has now become a formal political commitment. Technology minister Liz Kendall confirmed on Tuesday that the government is conducting a full review of its contract with Palantir for the NHS Federated Data Platformthe AI-enabled system awarded in 2023 to link health data across NHS organisations in England.

The review will determine whether to extend a £330 million deal under provisions allowing it to run for up to seven years, or to bring it to an end when the break clause falls in early 2027. That decision is now a matter of ministerial record, not just civil service speculation.

What The Federated Data Platform Actually Does

The NHS awarded Palantir the contract to provide software and manage the Federated Data Platform, designed to connect fragmented NHS databases and allow data from different systems to be shared and analysed. In practice, the FDP sits at the centre of how NHS England moves and uses patient data supporting waiting list management, hospital discharge planning, and clinical decision-making across trusts. 

A senior government figure has said officials are confident they could remove Palantir from NHS systems if they chose to, adding that the assessment was not prompted by specific dissatisfaction with the supplier. That careful distinction between a structural review rather than a performance failure defines the terms of the debate.

Parliament’s Case Against Renewal

MPs have urged the government to exercise the 2027 break clause in the NHS Federated Data Platform contract and either develop an in-house replacement or seek an alternative UK provider.

Its 70-page report found that Palantir had increased its presence despite a “clear mismatch with UK values” and possible risk to sensitive information, citing the company’s supply of software for the US military and immigration services, as well as its billionaire co-founder Peter Thiel’s political views. The report went further, warning that the government’s ambitions could be derailed at any time by a decision taken outside UK shores, based on the narrow interests of a foreign commercial or state actor.

That geopolitical framing has sharpened in the months since Labour took office. The committee’s concerns extend beyond the NHS; since 2020, Palantir and its partners have secured $750 million in government contracts spanning the NHS and the Ministry of Defence. The concentration of that exposure in a single US defence-sector firm has proved politically untenable for a significant block of MPs. 

Greater Manchester’s Integrated Care Board has continued to decline to join the Palantir-run platform, still waiting for evidence that it will be in the best interests of its population. That stance maintained by one of the largest ICBs in England is more than symbolic. It represents a practical test of whether the FDP can deliver the national coverage and interoperability it was procured to achieve.

Data Access, Genocide, And The Patient Trust Problem

Opposition to the contract has also been shaped by Palantir’s military contracts in active Palestine. The company holds contracts with the Israeli military and has been accused of aiding Israel’s genocide against the Palestinian people in Gaza a conflict in which the United Nations special rapporteur on human rights in the Palestinian territories and the International Court of Justice have both concluded that genocide is taking place. 

NHS staff, trade unions, and campaign groups argue that a company aiding Israel’s genocide has no place at the heart of a public health service. Campaigner group Foxglove, which has coordinated opposition to Palantir’s NHS role, has explicitly cited the company’s work with Israeli occupational forces as evidence of a value incompatibility with public health services. For many NHS workers, the objection is direct: they do not want patient data handled by a company whose technology is contributing to the killing of civilians and medical staff in Gaza and the West Bank. That concern has fed directly into the organised opposition that now has cross-party parliamentary backing.

Separately, London Mayor Sadiq Khan blocked a £50 million Metropolitan Police contract with Palantir last month, citing value for money concerns and questions about whether a company’s ethics should form part of public procurement criteria.

What Comes Next

The break clause could be triggered in early 2027, well before the government’s broader digital public services evaluation is complete, creating an awkward decision timeline. The government must either act on the committee’s recommendation, renegotiate the contract’s terms to address the sovereignty and data access concerns, or confirm an extension and defend that choice publicly.

The committee’s report argues that vendor lock-in should not be seen as inevitable and calls for a strategy to diversify public sector suppliers and strengthen digital resilience. Whether the government has the technical capacity, timeline, and appetite to execute a managed exit from a platform now embedded across NHS trusts in England is a different question altogether.

For the NHS digital transformation agenda and for the commissioners and care leaders whose services depend on the data infrastructure this contract underpins the answer matters considerably more than the politics around it.